In summary, our study suggests that NLG1 as a cell-membrane-integrated protein could be a therapeutic target in CRC to suppress anti-inflammatory immune responses in TME initiated by exosomes of the CRC cells. The gene discussed is NLGN1; the disease is colorectal carcinoma.